Cellectis S.A. (CLLS): Price and Financial Metrics


Cellectis S.A. (CLLS)

Today's Latest Price: $27.79 USD

2.32 (-7.71%)

Updated Jan 27 4:00pm

Add CLLS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CLLS Stock Summary

  • With a price/sales ratio of 14.97, Cellectis SA has a higher such ratio than 87.48% of stocks in our set.
  • With a year-over-year growth in debt of 133.44%, Cellectis SA's debt growth rate surpasses 90.47% of about US stocks.
  • Revenue growth over the past 12 months for Cellectis SA comes in at 241.74%, a number that bests 97.3% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CLLS, based on their financial statements, market capitalization, and price volatility, are AGIO, NERV, CYCN, SURF, and DRNA.
  • CLLS's SEC filings can be seen here. And to visit Cellectis SA's official web site, go to www.cellectis.com.

CLLS Stock Price Chart Interactive Chart >

Price chart for CLLS

CLLS Price/Volume Stats

Current price $27.79 52-week high $34.71
Prev. close $30.11 52-week low $7.32
Day low $27.31 Volume 368,772
Day high $29.57 Avg. volume 407,151
50-day MA $27.60 Dividend yield N/A
200-day MA $19.81 Market Cap 1.18B

Cellectis S.A. (CLLS) Company Bio


Cellectis SA is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. The company was founded in 1999 and is based in Paris, France.


CLLS Latest News Stream


Event/Time News Detail
Loading, please wait...

CLLS Latest Social Stream


Loading social stream, please wait...

View Full CLLS Social Stream

Latest CLLS News From Around the Web

Below are the latest news stories about Cellectis SA that investors may wish to consider to help them evaluate CLLS as an investment opportunity.

7 CRISPR Stocks for the Future of Medicine

In June 2012, the world changed forever. You probably didn’t even notice. It was in that month’s issue of the Science journal that U.C. Berkeley professor Jennifer Doudna and Umea University professor Emmanuelle Charpentier unveiled what the scientific community has since labeled the “scientific breakthrough of the century.” The breakthrough: CRISPR-Cas9 genetic editing systems.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Doudna and Charpentier invented a pair of “scissors” – called CRISPR-Cas9 systems – to cut specific DNA threads and modify genes inside of living organisms. How? Bacteria. Doudna and Charpentier noted a naturally occurring genome editing system in bacteria, wherein bacteria capture snippets of DNA from invading viruses and create new DNA segments call...

Yahoo | January 15, 2021

SIRION Biotech GmbH Licensed Its LentiBOOST™ Transduction Technology to Cellectis

MUNICH & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #Allogeneic--SIRION Biotech GmbH licensed its LentiBOOST™ transduction technology to Cellectis.

Business Wire | January 7, 2021

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of voting rights 12/31/202042,780,18648,847,575 About Cellectis Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the ...

Yahoo | January 6, 2021

The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia ...

Benzinga | December 29, 2020

Global Gene Therapy Market Report 2020-2030 Featuring Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics, Voyager Therapeutics, UniQure, Celgene, Cellectis and Sangamo Therapeutics

DUBLIN, Dec. 17, 2020 /PRNewswire/ -- The "Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Gene Therapy Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and…

PR Newswire | December 17, 2020

Read More 'CLLS' Stories Here

CLLS Price Returns

1-mo -10.84%
3-mo 69.87%
6-mo 77.01%
1-year 68.42%
3-year -16.62%
5-year 24.28%
YTD 2.70%
2020 58.06%
2019 2.82%
2018 -42.88%
2017 71.98%
2016 -45.38%

Continue Researching CLLS

Want to see what other sources are saying about Cellectis SA's financials and stock price? Try the links below:

Cellectis SA (CLLS) Stock Price | Nasdaq
Cellectis SA (CLLS) Stock Quote, History and News - Yahoo Finance
Cellectis SA (CLLS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8328 seconds.